SREBF2 and hepatocellular carcinoma: They proved that ASPP2 interacted with SREBP2 in the nucleus and reduced the transcriptional activity of SREBP2, which resulted in the down-regulation of the expression of the key enzymes in the mevalonate pathway, ultimately inhibiting the progression of HCC [13].